A Phase 4 interventional study of Ranibizumab in Wet Age-related Macular Degeneration (Wet AMD), sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-02-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
There are limited prospective data regarding the potential benefit and risks associated with switching between anti-VEGF therapies in patients with nAMD who have initially achieved a favorable response to the first anti-VEGF therapy used but subsequently have evidence of increasing disease activity despite continuation of therapy. This study will fill this knowledge gap by prospectively evaluating the effectiveness and safety of switching from aflibercept to ranibizumab in nAMD patients that have non - sustained response to initial treatment with aflibercept.
81 studies on the registry are indexed under Neovascularization, Pathologic; 6 are open to participants now.
Browse Neovascularization, Pathologic studies →Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exclusion criteria for ocular medical history and conditions for either eye:
Study eye exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm, intravitreal injection
Drug: Ranibizumab
0.5 mg, intravitreal injection
Mean change in Central Subfield Retinal Thickness (CSRT)
Change (in absolute and percentage terms) in central subfield retinal thickness (CSRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).
Time frame: at Day 90 (Month 3) and Day 180 (Month 6)
Mean change in Central Subfield Retinal Thickness (CSRT)
Change (in absolute and percentage terms) in central subfield retinal thickness (CSRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).
Time frame: Monthly, from baseline to Month 6
Mean change in Subfoveal Retinal Thickness (SRT)
Change (in absolute and percentage terms) in subfoveal retinal thickness (SRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).
Time frame: Monthly, from baseline to Month 6
Change in Central Subfield Retinal Volume (CSRV)
Change (in absolute and percentage terms) in subfoveal retinal thickness (SRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).
Time frame: Monthly, from baseline to Month 6
Mean change in Subretinal Fluid (SF)
Measured through Optical Coherence Tomography (OCT).
Time frame: Monthly, from baseline to Month 6
Mean change in Intra-Retinal Cystoid changes (IRCs) volume
Measured through Optical Coherence Tomography (OCT).
Time frame: Monthly, from baseline to Month 6
Mean change in Pigment Epithelial Detachments (PEDs)
Measured through Optical Coherence Tomography (OCT).
Time frame: Monthly, from baseline to Month 6
Mean change of Best-Corrected Visual Acuity (BCVA)
Best-corrected visual acuity (BCVA) will be assessed in a sitting position using subjective refraction and ETDRS-like visual acuity testing charts.
Time frame: Monthly, from baseline to Month 6
Rate of change in Subfoveal Retinal Thickness (SRT)
Rates will be assessed with the proportion of patients with changes.
Time frame: Monthly, from baseline to Month 6
Rate of change in Central Subfield Retinal Thickness (CSRT)
Rates will be assessed with the proportion of patients with changes.
Time frame: Monthly, from baseline to Month 6
Rate of change in Intra-Retinal Cystoid (IRCs)
Rates will be assessed with the proportion of patients with changes.
Time frame: Monthly, from baseline to Month 6
Rate of change in Pigment Epithelial Detachments (PEDs)
Rates will be assessed with the proportion of patients with changes.
Time frame: Monthly, from baseline to Month 6
Rate of Dry Retina
Rates will be assessed with the proportion of patients with changes.
Time frame: Monthly, from baseline to Month 6
No study locations are listed for this record.
Start is estimated for Mar 2016; primary completion for Dec 2017, 21 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab
Neovascularization, Pathologic →